Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
Immuneering (Nasdaq: IMRX) will report third quarter 2025 financial results and share new clinical case studies on Wednesday, November 12, 2025, after market close.
Trial investigators will present case studies from first-line pancreatic cancer patients treated with atebimetinib plus FOLFIRINOX in the company’s Phase 2a study. A conference call and webcast are scheduled for 1:30 pm PT / 4:30 pm ET on November 12, 2025.
Live access via webcast or by dialing the listed U.S. and international numbers (conference ID 7742025). A replay will be available from the Investors section of the company website for one year; registration via the Events webcast link is required.
Immuneering (Nasdaq: IMRX) verrà pubblicato risultati finanziari del terzo trimestre 2025 e verranno condivisi nuovi studi clinici di casi mercoledì 12 novembre 2025, dopo la chiusura del mercato.
I ricercatori della sperimentazione presenteranno studi di casi di pazienti con cancro pancreatico in stadio iniziale trattati con atebimetinib più FOLFIRINOX nello studio di fase 2a dell'azienda. Una conferenza telefonica e un webcast sono previsti per le 13:30 PT / 16:30 ET di 12 novembre 2025.
Accesso in diretta tramite webcast o digitando i numeri statunitensi e internazionali elencati (ID conferenza 7742025). Una replica sarà disponibile dall'area Investitori del sito web dell'azienda per un anno; la registrazione tramite il link webcast degli Eventi è necessaria.
Immuneering (Nasdaq: IMRX) informará resultados financieros del tercer trimestre de 2025 y compartirá nuevos estudios clínicos de casos el miércoles 12 de noviembre de 2025, después del cierre del mercado.
Investigatores de los ensayos presentarán estudios de casos de pacientes con cáncer de páncreas en primera línea tratados con atebimetinib más FOLFIRINOX en el estudio de fase 2a de la empresa. Se ha programado una conferencia telefónica y un webcast para las 1:30 p. m. PT / 4:30 p. m. ET el 12 de noviembre de 2025.
Acceso en vivo a través de webcast o llamando a los números estadounidenses e internacionales listados (ID de conferencia 7742025). Una repetición estará disponible en la sección de Inversores del sitio web de la empresa durante un año; se requiere registro a través del enlace de webcast de Eventos.
Immuneering (나스닥: IMRX)은 2025년 3분기 재무성과를 발표하고 2025년 11월 12일 수요일, 장 마감 이후 새로운 임상 사례 연구를 공유합니다.
임상 연구자들은 회사의 2a상 연구에서 아테비메틴- FOLFIRINOX 병합 치료를 받은 1차 췌장암 환자의 사례 연구를 발표할 예정입니다. 컨퍼런스 콜 및 웹캐스트는 2025년 11월 12일 태평양 표준시 1:30 pm / 동부표준시 4:30 pm에 예정되어 있습니다.
웹캐스트를 통한 라이브 접속 또는 미국 및 국제 전화번호로 연결(회의 ID 7742025). 회사 웹사이트의 투자자 섹션에 있는 영역에서 1년간 재방송이 제공되며, 이벤트 웹캐스트 링크를 통한 등록이 필요합니다.
Immuneering (Nasdaq: IMRX) publiera les résultats financiers du troisième trimestre 2025 et partagera de nouvelles études de cas cliniques mercredi 12 novembre 2025, après la clôture du marché.
Les investigateurs de l’essai présenteront des études de cas de patients atteints d’un cancer du pancréas en première ligne traités par atebimetinib plus FOLFIRINOX dans l’étude de phase 2a de la société. Une conférence téléphonique et un webcast sont prévus pour le 12 novembre 2025 à 13h30 PT / 16h30 HE.
Accès en direct par webcast ou en composant les numéros américains et internationaux indiqués (ID de conférence 7742025). Une rediffusion sera disponible dans la section Investisseurs du site web de l’entreprise pendant un an; l’inscription via le lien webcast des Événements est requise.
Immuneering (Nasdaq: IMRX) wird finanzergebnisse zum dritten Quartal 2025 bekannt geben und neue klinische Fallstudien am Mittwoch, dem 12. November 2025, nach Börsenschluss vorstellen.
Studienleiter werden Fallstudien von Erstlinien-Pankreaskrebs-Patienten vorstellen, die mit Atebimetinib plus FOLFIRINOX in der Phase-2a-Studie des Unternehmens behandelt wurden. Eine Telefonkonferenz und ein Webcast sind für den 12. November 2025 um 13:30 PT / 16:30 ET vorgesehen.
Live-Zugang per Webcast oder durch Wählen der in den USA und international aufgeführten Nummern (Conference-ID 7742025). Eine Wiedergabe wird im Bereich Investoren der Unternehmenswebsite für ein Jahr verfügbar sein; eine Registrierung über den Webcast-Link zu den Veranstaltungen ist erforderlich.
إيمونيورينغ (ناسداك: IMRX) ستعلن عن النتائج المالية للربع الثالث من 2025 وتشارك دراسات حالة سريرية جديدة يوم الأربعاء الموافق 12 نوفمبر 2025، بعد إغلاق السوق.
سيقدم باحثو التجربة دراسات حالة لمرضى سرطان البنكرياس من الخط الأول المعالجين بـ اتوبيمتينيب زائد FOLFIRINOX في دراسة المرحلة 2a للشركة. من المقرر إجراء مكالمة مؤتمر وويبكاست في 1:30 مساءً بتوقيت المحيط الهادئ / 4:30 مساءً بتوقيت شرق الولايات المتحدة في 12 نوفمبر 2025.
الوصول المباشر عبر الويب كاست أو بالاتصال بالأرقام الأمريكية والدولية المذكورة (معرّف المؤتمر 7742025). ستتوفر إعادة بث من قسم المستثمرين في موقع الشركة على الويب لمدة سنة واحدة؛ التسجيل عبر رابط الويبكاست للفعاليات مطلوب.
- None.
- None.
- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators –
- Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET -
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financial results and trial investigators will provide case studies from first-line pancreatic cancer patients treated in the company’s Phase 2a study of atebimetinib in combination with FOLFIRINOX, on Wednesday, November 12, 2025, after the close of market. Immuneering will host a conference call and webcast at 1:30 pm PT / 4:30 pm ET on the same day.
Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 7742025. A webcast replay will be available from the “Investors” section of the Company’s website here.
To access the replay, please register via the webcast link on the Events page. The webcast will be available for one year following the completion of the call.
About Immuneering
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Carson Creehan
202-878-8330
carson.creehan@padillaco.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When will Immuneering (IMRX) report third quarter 2025 results and host the webcast?
What clinical data will Immuneering (IMRX) present on November 12, 2025?
How can investors listen to the Immuneering (IMRX) November 12 conference call?
Will a replay of the Immuneering (IMRX) webcast be available after the call?
What phase is the atebimetinib plus FOLFIRINOX study discussed by Immuneering (IMRX)?
What time zones are used for the Immuneering (IMRX) November 12 event?
